FDA-approved carbonic anhydrase inhibitors reduce amyloid β pathology and improve cognition, by ameliorating cerebrovascular health and glial fitness.

导出 OA

翻译打印收藏纠错

第一作者： Elisa,Canepa

第一单位： Alzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA.

作者： Elisa,Canepa ^[1] ; Rebecca,Parodi-Rullan ^[1] ; Rafael,Vazquez-Torres ^[1] ; Begona,Gamallo-Lana ^[2] ; Roberto,Guzman-Hernandez ^[1] ; Nicole L,Lemon ^[1] ; Federica,Angiulli ^[1] ; Ludovic,Debure ^[3] ; Marc A,Ilies ^[4] ; Leif,Østergaard ^[5] ; Thomas,Wisniewski ^[3] ; Eugenio,Gutiérrez-Jiménez ^[5] ; Adam C,Mar ^[2] ; Silvia,Fossati ^[1]

作者单位： Alzheimer's Center at Temple, Department of Neural Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, USA. ^[1] Department of Neuroscience and Physiology, Neuroscience Institute, NYU Grossman School of Medicine, New York, New York, USA. ^[2] Department on Neurology, Center for Cognitive Neurology, NYU Grossman School of Medicine, New York, New York, USA. ^[3] Department of Pharmaceutical Sciences and Moulder Center for Drug Discovery Research, Temple University School of Pharmacy, Temple University, Philadelphia, Pennsylvania, USA. ^[4] Center of Functionally Integrative Neuroscience (CFIN), Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. ^[5]

关键词 Alzheimer's disease amyloid beta astrocytes carbonic anhydrase inhibitors cerebral amyloid angiopathy cerebrovascular dysfunction clearance endothelial cells microglia neuroinflammation